Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors.

摘要: PURPOSETo review published controlled clinical trials examining the benefit of escalated chemotherapy in patients with hematologic and solid malignancies.METHODSStudies were obtained by searching Medline CancerLit bibliographies trials. We reviewed studies that examined dose-intense (DI) alone, combination hematopoietic colony-stimulating factors (CSFs), or high-dose therapy (HDT) autologous bone marrow support (ABMT).RESULTSDI without CSF ABMT has not been shown to improve overall outcome any tumor except consolidative acute myelogenous leukemia (AML). In tumors, many suggest less than standard-intensity is suboptimal, but few higher compared standard-dose have a significant difference outcome. No convincingly demonstrated improved survival (OS) DI support. The use HDT sho...